Cogentin

Cogentin

Cogentin Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Safe use in pregnancy has not been established.

COGENTIN may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.

When COGENTIN is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including COGENTIN, in combination with phenothiazines and/or tricyclic antidepressants.

Since COGENTIN contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

For use as an adjunct in the therapy of all forms of parkinsonism (see DOSAGE AND ADMINISTRATION).

Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines).

History

There is currently no drug history available for this drug.

Other Information

Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesul-fonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is:

Structural Formula

Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54.

COGENTIN (benztropine mesylate) is supplied as a sterile injection for intravenous and intramuscular use.

Each milliliter of the injection contains:

Benztropine mesylate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 mg

Sodium chloride . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 mg

Water for injection q.s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 mL

Cogentin Manufacturers


  • Oak Pharmaceuticals, Inc. (Subsidiary Of Akorn, Inc.)
    Cogentin (Benztropine Mesylate) Injection [Oak Pharmaceuticals, Inc. (Subsidiary Of Akorn, Inc.)]

Login To Your Free Account